Literature DB >> 33211640

Diversity of Carbapenem Resistance Mechanisms in Clinical Gram-Negative Bacteria in Pakistan.

Linda Hadjadj1, Muhammad Ali Syed2, Shahid Ahmad Abbasi3, Jean-Marc Rolain1, Bushra Jamil4.   

Abstract

Antibiotic resistance is a health challenge worldwide. Carbapenem resistance in Gram-negative bacteria is a major problem since treatment options are very limited. Tigecycline and colistin are drugs of choice in this case, but resistance to these drugs is also high. The aim of this study was to describe the diversity of resistance mechanisms in carbapenem-resistant clinical Gram-negative bacteria from Pakistan. Carbapenem-hydrolyzing enzyme-encoding genes were detected using PCR and DNA sequencing and clonal types determined by multilocus sequence typing (MLST). Forty-four carbapenem-resistant isolates were collected from the microbiology laboratory of Fauji Foundation Hospital and Al-Syed Hospital, Rawalpindi, Pakistan, including Klebsiella spp., Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter cloacae, and Achromobacter xylosoxidans. blaNDM-1, blaNDM-4, blaNDM-5, blaNDM-7, blaOXA-48, and blaOXA-181 were detected in Enterobacteriaceae; blaOXA-23, blaOXA-72, and blaNDM-1 in A. baumannii, and blaVIM-6 and blaVIM-11 in P. aeruginosa. MLST analysis revealed several predominant clonal types: ST167 in E. coli, ST147 in Klebsiella pneumoniae, ST2 in Acinetobacter, and ST664 in P. aeruginosa. In Acinetobacter, a new clonal type was observed for the first time. To the best of our knowledge, this is the first study describing the clonality and resistance mechanisms of carbapenem-resistant Gram-negative bacteria in Pakistan.

Entities:  

Keywords:  Pakistan; antibiotic resistance; carbapenem; multilocus sequence type; resistance

Mesh:

Substances:

Year:  2020        PMID: 33211640     DOI: 10.1089/mdr.2019.0387

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  6 in total

1.  Dissemination of carbapenemase-producing Enterobacterales in the community of Rawalpindi, Pakistan.

Authors:  Amina Habib; Stéphane Lo; Khanh Villageois-Tran; Marie Petitjean; Shaheen Akhtar Malik; Laurence Armand-Lefèvre; Etienne Ruppé; Rabaab Zahra
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

2.  Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.

Authors:  Luke Diorio-Toth; Sidra Irum; Robert F Potter; Meghan A Wallace; Muhammad Arslan; Tehmina Munir; Saadia Andleeb; Carey-Ann D Burnham; Gautam Dantas
Journal:  Microbiol Spectr       Date:  2022-05-31

3.  Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial Pseudomonas aeruginosa.

Authors:  Maria Muddassir; Sadaf Munir; Almas Raza; Ahmad Basirat; Muddassir Ahmed; Umar Farooq; Syed Shoaib Ahmed; Syed Zeeshan Haider Naqvi
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

4.  Use of Nanopore Sequencing to Characterise the Genomic Architecture of Mobile Genetic Elements Encoding bla CTX-M-15 in Escherichia coli Causing Travellers' Diarrhoea.

Authors:  Matthew T Bird; David R Greig; Satheesh Nair; Claire Jenkins; Gauri Godbole; Saheer E Gharbia
Journal:  Front Microbiol       Date:  2022-03-29       Impact factor: 5.640

5.  Insights on the performance of phenotypic tests versus genotypic tests for the detection of carbapenemase-producing Gram-negative bacilli in resource-limited settings.

Authors:  Noha A Kamel; Sally T Tohamy; Ibrahim S Yahia; Khaled M Aboshanab
Journal:  BMC Microbiol       Date:  2022-10-14       Impact factor: 4.465

6.  Molecular Epidemiology of Extensively-Drug Resistant Acinetobacter baumannii Sequence Type 2 Co-Harboring bla NDM and bla OXA From Clinical Origin.

Authors:  Hasan Ejaz; Mahtab Ahmad; Sonia Younas; Kashaf Junaid; Khalid Omer Abdalla Abosalif; Abualgasim Elgaili Abdalla; Ayman Ali Mohammed Alameen; Mohammed Yagoub Mohammed Elamir; Syed Nasir Abbas Bukhari; Naveed Ahmad; Muhammad Usman Qamar
Journal:  Infect Drug Resist       Date:  2021-05-25       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.